A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) - A536-03

Trial Profile

A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) - A536-03

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Luspatercept (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms PACE-MDS
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 11 Dec 2017 According to a Acceleron Pharma media release, preliminary results were presented at the 59th Annual Meeting of the American Society of Hematology (ASH)
    • 10 Dec 2017 Results published in the Acceleron Pharma Media Release
    • 01 Nov 2017 According to an Acceleron Pharma media release, data will be presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top